After reading Brian's Bullish opener to this round of Dueling Fools, I'm even more convinced that now is as good a time as any to establish a position in GlaxoSmithKline
However, I'm still not certain that Glaxo's outlook is strong enough to warrant a bullish outlook, especially compared with other health-care investment alternatives. Brian did point out Glaxo's strong drug pipeline, with 158 compounds in development and nearly 20% in phase 3 trials, meaning they are close to coming to market should the last phase in clinical trials prove successful.
Hopefully, Brian quantifies in his side of the rebuttals what Glaxo's pipeline might mean for growth, because as far as I can tell it won't do more than lead to annual sales improvements of a couple of percent in the years to come. Earnings growth will likely be higher, but it's hard to grow and spend billions in research and development to keep the pipeline full of potential when the sales base is $46 billion.
Fool contributor Ryan Fuhrmann is long shares of Pfizer and Amgen but has no financial interest in any other company mentioned. Feel free to email him with feedback or to discuss any companies mentioned further. The Fool has an ironclad disclosure policy.